Falling At The Start Line: Chinese Firms Face Multiple Commercial Challenges Beyond Price, Coverage

First-In-Class But Low Revenues

Sales of a global first-in-class dermatology drug that gained its first approval in China are falling well behind those of its overseas counterpart. Brian Yang takes a deeper look into the multiple underlying factors determining success in the world's second-largest pharma market beyond pricing and reimbursement coverage, including complex hospital entry, dual channels and competition considerations. 

China NDA in 2021 sized 1200
Chinese drug makers face commercial challenges beyond pricing, coverage • Source: Shutterstock

For a Chinese domestically developed, first-in-class, topical non-steroidal treatment, and the first new drug for plaque psoriasis in 25 years, benvitimod - also known as tapinarof and WBI-1001 - encountered a surprisingly uphill battle to gain commercial success on its home turf. Meanwhile, its overseas counterpart has attracted large investment and enjoyed considerably more success.

Receiving its first approval globally from China's National Medical Products Administration in 2019, the therapeutic aryl hydrocarbon receptor (AhR) modulating...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Global Vision

More from In Vivo

Podcast: ADDF’s Karen Harris On Investing In Alzheimer’s Like A VC

 
• By 

A discussion with Karen Harris, CFO of the Alzheimer's Drug Discovery Foundation, about the foundation's investment strategy, biotech and investor sentiment at the recent BIO conference and what innovations give her hope for Alzheimer's patients.

Turning Defense Into Attack: Snapshots Of A Changing Medtech Market And How To Respond

 
• By 

Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.

AI Agents Set To Reshape Biopharma’s Workforce And Operations

 
• By 

While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.